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Background 
Comorbidities and complications associated with type 2 diabetes (T2D) increase with age, 
making treatment of elderly people with T2D particularly challenging. Clinical data, 
particularly on the effect of antihyperglycemic treatment on cardiovascular (CV) events, are 
limited in elderly patients (1). Regulatory bodies, such as the Food and Drug administration 
(FDA) and the European Medicines Agency (EMA), have recommended the collection of 
comprehensive data in elderly patients with diabetes, with particular focus on patients aged 
≥75 years to inform appropriate treatment of this growing population (2,3). 
 
Glucagon-like peptide-1 (GLP-1) agonists are one of the newer classes of antihyperglycemic 
agents recommended for the treatment of T2D because of their high glycemic efficacy with 
low intrinsic risk of hypoglycemia and promotion of weight loss (4). The Liraglutide Effect 
and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) CV 
outcomes trial reported a 13% reduction in major adverse cardiovascular events (MACE) with 
liraglutide treatment versus placebo in patients with T2D at high risk for CV events (5). 
 
Objective 
This post hoc analysis examines the CV effects of liraglutide versus placebo in patients aged 
≥75, 60–<75 and <60 years. 
 
Methods and findings 
Study design, methods and statistical analysis have been described previously (5). The primary 
endpoint was the time from randomization to first occurrence of a MACE, defined as CV death, 
non-fatal myocardial infarction (MI), or non-fatal stroke. Safety endpoints included the 
frequency of serious adverse events (SAEs) and medical events of special interest (MESIs) (5). 
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Time-to-event analysis was adjusted for baseline covariates (including CV status at baseline 
and a wider range of CV factors such as smoking) (5).  
Of the 9340 patients randomized in the LEADER trial, 836 were aged ≥75, 6183 were aged 
60–<75 and 2321 were aged <60 years. All patients in the <60 years age group had existing 
CV disease (CVD), according to the eligibility criteria. This analysis focuses on patients aged 
60–<75 and >75 years, encompassing patients with both existing CVD and CVD risk factors. 
 
Overall, the baseline characteristics were matched between the treatment groups in the age 
subgroups (Table 1). The primary outcome occurred more frequently in patients aged ≥75 
versus those aged 60–<75 years, irrespective of treatment.  
A 34% and 29% risk reduction in the frequency of MACE and MACE expanded outcomes, 
respectively, was observed with liraglutide versus placebo in patients aged ≥75 years. These 
reductions appeared less prominent between the two treatment groups in patients aged 60−<75 
years (Figure 1) (p-interaction=0.054 and 0.083, respectively).  
Patients randomized to liraglutide also experienced a reduced frequency of other CV outcomes 
versus placebo, irrespective of age group (Figure 1).  
A 35% risk reduction in all-cause death was observed with liraglutide versus placebo in patients 
aged ≥75 years. This reduction appeared less accentuated between the two treatment groups in 
patients aged 60–<75 years (Figure 1) (p-interaction=0.09). 
Overall, a higher proportion of patients aged ≥75 years reported SAEs or non-serious MESIs 
compared with patients aged 60–<75 years. Across the two subgroups, no notable difference 
between the treatment groups was observed. The most common adverse events were neoplasms 
and gastrointestinal disorders (diarrhea, nausea and vomiting) in both subgroups. The 
proportion of patients with gastrointestinal disorders and the incidence of acute gallstone 
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disease were higher in patients treated with liraglutide versus placebo, irrespective of the age 
subgroup. 
 
Discussion 
This post hoc analysis extends the results from the primary LEADER report (2), specifically to 
the substantial number of elderly patients at high risk of CV events included in the trial, 
demonstrating a significant reduction in frequency of the primary MACE and expanded MACE 
outcomes and all-cause death with liraglutide versus placebo. The benefits appeared more 
pronounced in patients aged ≥75 years versus those aged 60–<75 years. Our analysis provides 
important information regarding a special population for which limited clinical trial data have 
been available. 
 
Limitations of this analysis include the relative small size of the subgroup ≥75 years versus the 
overall population, short-follow-up time, and the exploratory nature of post hoc analysis. 
 
These results can help physicians in clinical decision making on optimal management of T2D 
in elderly patients, a vulnerable population for whom treatment options with evident benefits 
regarding important clinical endpoints are limited. 
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Table 1. Baseline demographics and characteristics by age at baseline 1 
 Age <60 years*  Age 60–<75 years Age ≥75 years  
 Liraglutide 
(N=1197 ) 
Placebo 
(N=1124 ) 
Liraglutide 
(N=3053) 
Placebo 
(N=3130) 
Liraglutide 
(N= 418) 
Placebo 
(N= 418) 
Male, n (%) 775 ( 64.7)      761 ( 67.7)     1968 (64.5)     1967 (62.8)     268 (64.1) 264 (63.2) 
Age, years 55.3 (2.8) 55.3 (2.8) 65.8 (4.1) 65.8 (4.1) 77.9 (2.9) 78.0 (3.1) 
BMI, kg/m2 33.4 (6.8)      33.4 (6.9)         32.4 (6.2)      32.4 (6.1)    30.7 (5.4) 30.5 (4.8) 
Diabetes duration, years 10.9 (7.0)       10.4 (6.8)            13.0 (7.7)       13.3 (8.1)      17.0 (10.3) 15.8 (9.1) 
HbA1c, % (mmol/mol) 9.0 (1.7)        8.9 (1.6)  8.7 (1.5)             8.6 (1.4)  8.4 (1.4) 8.3 (1.3) 
CV history (MI or stroke) 626 (52.3) 585 (52.0) 1089 (35.7)           1083 (34.6) 150 (35.9) 159 (38.0) 
History of MI, n (%) 500 (41.8)            473 (42.1)        847 (27.7)            812 (25.9)   117 (28.0) 115 (27.5) 
History of stroke, n (%) 173 (14.5)            142 (12.6)      332 (10.9)            361 (11.5) 41 (9.8)  54 (12.9) 
Smoking status       
Current smoker, n (%) 210 (17.5)            209 (18.6)     343 (11.2)            339 (10.8)    14 (3.3) 15 (3.6) 
Never smoked, n (%) 488 (40.8)            411 (36.6)   1267 (41.5)           1310 (41.9)     195 (46.7) 199 (47.6) 
Previous smoker, n (%) 499 (41.7)            504 (44.8) 1443 (47.3)           1481 (47.3)       209 (50.0) 204 (48.8) 
Systolic blood pressure, mmHg 133.4 (17.3)          132.7 (17.0) 136.8 (17.7)          136.7 (17.7)          136.5 (19.4) 138.3 (18.6) 
Diastolic blood pressure, mmHg 79.6 (9.8)          78.9  (9.7)     77.0 (10.2)          76.7 (10.2)         72.2 (10.4) 73.7 (10.3) 
Heart rate, beats per minute 74.0  (10.9)           74.2 (10.6) 72.5 (11.4)           72.2 (11.5) 70.1 (11.4) 70.7 (12.2) 
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 Age <60 years*  Age 60–<75 years Age ≥75 years  
 Liraglutide 
(N=1197 ) 
Placebo 
(N=1124 ) 
Liraglutide 
(N=3053) 
Placebo 
(N=3130) 
Liraglutide 
(N= 418) 
Placebo 
(N= 418) 
eGFR MDRD, mL/min/1.73 m2  89.8 (28.3)           90.3 (27.8)          78.8 (26.3)           79.2 (26.3)     62.9 (23.2) 65.0 (22.1) 
Severe (<30), n (%) 25 (2.1)              23 (2.0)     63 (2.1)              63 (2.0)      29 (6.9) 21 (5.0) 
Moderate (30–59), n (%) 148 (12.4)            130 (11.6)   672 (22.0)            641 (20.5)     179 (42.8) 164 (39.2) 
Mild (60–89), n (%) 422 (35.3)            380 (33.8) 1349 (44.2)           1420 (45.4)   161 (38.5) 175 (41.9) 
Normal (≥90), n (%) 602 (50.3)            591 (52.6)   969 (31.7)           1006 (32.1)         49 (11.7) 58 (13.9) 
Total cholesterol, mmol/L 4.5 (1.2) 4.5 (1.4) 4.4 (1.2) 4.4 (1.1) 4.2 (1.1) 4.3 (1.0) 
LDL cholesterol, mmol/L 2.4 (1.0) 2.4 (1.0) 2.3 (0.9)    2.3 (0.9)    2.2 (0.9) 2.3 (0.9) 
HDL cholesterol, mmol/L 1.1 (0.3) 1.1 (0.3) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 1.3 (0.4) 
Triglycerides, mmol/L 2.3 (1.6) 2.4 (2.5) 2.0 (1.4) 2.0 (1.4) 1.8 (1.0) 1.7 (1.0) 
Data are mean (SD) or n (%) unless otherwise stated.  2 
*All patients in the <60 years age group had a history of CV disease in accordance with the eligibility criteria.  3 
BMI, body mass index; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high-4 
density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; MDRD, calculated using the Modified Diet in Renal 5 
Disease equation; n, number of patients, N, total number of patients, SD, standard deviation. 6 
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Figure legend 7 
 8 
Figure 1. First occurrence of the primary composite MACE outcome and secondary 9 
outcomes, stratified by age at baseline 10 
*p-value is for the interaction between treatment and subgroup. A significant p-interaction value (<0.05) indicates 11 
that the treatment effect is not consistent across subgroups. Analyses were adjusted for baseline covariates 12 
(including CV status at baseline as defined in the primary analysis (5) and a wider range of CV factors such as 13 
smoking). No adjustment for multiple testing was performed. 14 
 AP, angina pectoris; CI, confidence interval; CV, cardiovascular; HF, heart failure; MACE, major adverse 15 
cardiovascular events; MI, myocardial infarction; n, number of patients; PYO, patient-years of observation.16 
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